Pascalis Vergidis, MD @pascalisid.bsky.social · 19/04/2026Bismarck Bisono presenting @escmid.bsky.social on invasive aspergillosis in patients with chronic lymphocytic leukemia 020
Pascalis Vergidis, MD @pascalisid.bsky.social · 15/04/2026Y ou know about invasive aspergillosis in AML. Do you want to learn what happens in Chronic Lymphocytic Leukemia? Dr. Bismarck Bisono will discuss risk factors and outcomes. First presentation in IFI session @escmid.bsky.social 020
Pascalis Vergidis, MD @pascalisid.bsky.social · 28/03/2026Mary Bowden, MD was fired by her own institution for prescribing ivermectin to treat Covid-19 (among other reasons). She has recently drawn attention for targeting doctors starting their training. We (as medical community) are not obligated to engage with or amplify her posts. 000
Pascalis Vergidis, MD @pascalisid.bsky.social · 25/03/2026Long term Mpox sequelae www.acpjournals.org/doi/10.7326/...acpjournals.orgSummary for Patients: Long-Term Mpox Sequelae 11 to 18 Months After Acute Illness | Annals of Internal Medicine 000
Pascalis Vergidis, MD @pascalisid.bsky.social · 25/03/2026Serofast in syphilis refers to a state where patients have persistently reactive nontreponemal test titers despite successful treatment, without evidence of treatment failure or reinfection. 010
Pascalis Vergidis, MD @pascalisid.bsky.social · 24/01/2026Department of Medicine Staff Awards @mayocliniccancer.bsky.social Honored to be a Member of the amazing CAR-T cell therapy team. 000
Pascalis Vergidis, MD @pascalisid.bsky.social · 23/01/2026Mycology Lab for the medical students at Mayo Clinic Alix School of Medicine. We reviewed morphological differences between Aspergillus and Mucorales. 140
Pascalis Vergidis, MD @pascalisid.bsky.social · 22/01/2026Included in this year’s Mycology Lecture for the medical students at Mayo Clinic Alix School of Medicine. Trichophyton indotinae, an emerging fungal threat 000
Pascalis Vergidis, MD @pascalisid.bsky.social · 17/01/2026Microbiology course at Mayo Clinic Alix School of Medicine. We reviewed 4 case of tuberculosis with a focus on social determinants of health. Excellent discussion led by our social worker, Mariah Thompson, and Dr. Zami Temesgen, principal investigator Mayo Clinic Center for Tuberculosis. 230
Pascalis Vergidis, MD @pascalisid.bsky.social · 14/01/2026Bacteriology Lab for the medical students at Mayo Clinic Alix School of Medicine led by Dr. Bobbi Pritt. We had 12 stations. All about Gram stains and cultures! Note the green metallic sheen of E. coli on Eosin Methylene Blue (EMB) agar. 120
Pascalis Vergidis, MD @pascalisid.bsky.social · 12/01/2026Introduction to Microbiology for the medical students at the Mayo Clinic Alix School of Medicine We discussed this MMWR publication which brought us back to the onset of the #HIV epidemic. 140
Pascalis Vergidis, MD @pascalisid.bsky.social · 06/12/2025Looking forward to our journal club #MayoClinic Infectious Disease Fellowship. Adjunctive corticosteroids in hypoxemic patients with non-HIV Pneumocystis pneumonia. No difference in 28-day mortality. However, need for mechanical ventilation was lower in the steroid group. 250
Pascalis Vergidis, MD @pascalisid.bsky.social · 05/12/2025As a member of the ABIM Infectious Disease Approval Committee, I would like to congratulate those who recently passed their Boards. You are all committed to delivering exceptional patient care and upholding the highest standards in Medicine. 130
Reposted by Pascalis Vergidis, MDJoanna Schaenman, MD, PhD @jschaenmanmd.bsky.social · 20/10/2025How best to treat invasive aspergillosis? @pascalisid.bsky.social reviewing key clinical studies informing this choice - important to monitor vori levels , NB: AmB <vori=isavu @idweek.bsky.social #IDWeek2025 #TxID #IDSky 151
Pascalis Vergidis, MD @pascalisid.bsky.social · 18/10/2025Please join us this Monday 8-9 am at IDWeek. Difficult-to-treat mold infections. Dimitrios Farmakiotis will be discussing treatment of mucormycosis. I will be discussing aspergillosis. 3102
Reposted by Pascalis Vergidis, MDUniversity of Minnesota Infectious Diseases @umn-idim.bsky.social · 07/10/2025There’s now an app for all things fungi 🦠🍄 Dr. Matthew Pullen, Assistant Professor at the University of Minnesota, helped launch Dr Fungus—a free app that brings the trusted resource to your phone. Explore fungal infections, antifungal treatments, and case-based learning—all in one place.drfungus.orgHome - Doctor FungusWelcome to Doctor Fungus! An Educational Website of theMycoses Study Group Education and Research Consortium (MSGERC) [View Legal Information] Where to Start Mycology Case of the Month An Introducti... 24316
Reposted by Pascalis Vergidis, MDAlex Sundermann, DrPH @sundermannaj.bsky.social · 10/07/2025🆕 MMWR: In NYC, NDM-CRE just surpassed KPC-CRE for the first time. And nearly 75% of these cases had no long-term care facility link This is a changing landscape of antibiotic resistance - happening across US #IDSky 📄: www.cdc.gov/mmwr/volumes... 383
Reposted by Pascalis Vergidis, MDIlan Schwartz @germhuntermd.bsky.social · 20/06/2025Detection of Mucorales antigen in BAL samples using a newly developed lateral-flow device A Mucorales antigen test is sorely needed This one had Sn of 76.92%, Sp of 75.51%, respectively, PPV 45.45%, and a NPV 92.5% (Not good enough but could augment qPCR) journals.asm.org/doi/10.1128/... 2228
Pascalis Vergidis, MD @pascalisid.bsky.social · 13/06/2025Join us for a panel discussion on “Leveraging Partnerships to Fight Fungal Diseases” June 19 2.55-3.25 pm @ASMicrobiology Dallas Smith @CDCgov Sean Zhang, Fungal Diagnostics Laboratory Consortium Rob Purdie, MYCology Advocacy, Research & Education Zachary Rubin @lapublichealth Me @MSG_ERC 251
Pascalis Vergidis, MD @pascalisid.bsky.social · 12/06/2025Visited the historic city of Philadelphia to attend the American Board of Internal Medicine (ABIM) New Governance Orientation. Looking forward to serving on the Infectious Disease Approval Committee. Of the profession, for the public 130
Pascalis Vergidis, MD @pascalisid.bsky.social · 08/06/2025Synthesis of the available literature on the use of CMV-specific T-cell therapy in adult and pediatric HSCT and SOT recipients. Several patients on concurrent antivirals, which confounded the effectiveness of VSTs @CIDJournal @transplantidnet.bsky.social academic.oup.com/cid/advance-...academic.oup.comVirus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping ReviewCytomegalovirus-specific T cells have been used in studies of primarily adult hematopoietic stem cell transplant recipients. Heterogenous trial design and 050
Pascalis Vergidis, MD @pascalisid.bsky.social · 06/06/2025Dr. Jeniel Nett discussing biofilm at the 2025 Scientific Meeting on Candida auris @msgerc.bsky.social 020
Pascalis Vergidis, MD @pascalisid.bsky.social · 06/06/2025High Kaposi sarcoma-associated herpesvirus seroprevalence in donors and recipients with HIV, particularly among MSM. Reassuringly, disease was rare. @transplantidnet.bsky.social academic.oup.com/cid/advance-...academic.oup.comKaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With Human Immunodeficiency Virus in the United StatesThe prevalence of Kaposi sarcoma–associated herpesvirus (KSHV) was high among kidney donor and transplant recipients with HIV. Posttransplant KSHV-associat 020
Pascalis Vergidis, MD @pascalisid.bsky.social · 02/06/2025In a phase 3 clinical trial, pemivibart provided prophylactic efficacy against COVID-19 in immunocompromised patients and individuals at risk for exposure. Four of 623 participants experienced anaphylactic reactions @transplantidnet.bsky.social academic.oup.com/cid/advance-...academic.oup.comSafety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)AbstractBackground. We report an interim analysis of safety and efficacy of pemivibart in individuals with (cohort A) or without (cohort B) significant imm 030
Reposted by Pascalis Vergidis, MDIlan Schwartz @germhuntermd.bsky.social · 15/05/2025Increasing Fluconazole Resistance in Candida parapsilosis: A 10-Year Analysis of Blood Culture Isolates at a US Reference Laboratory (2015–2024) Fluco-R C parapsilosis ⬆️ from 8.2% to 20.3% in BCx isolates tested @ Mayo Jack McHugh ... @pascalisid.bsky.social academic.oup.com/jid/advance-... 062
Reposted by Pascalis Vergidis, MDIlan Schwartz @germhuntermd.bsky.social · 31/03/2025This #TransDayofVisibility 🏳️⚧️ Please know: We see you, & we will continue to fight for you. 0103
Pascalis Vergidis, MD @pascalisid.bsky.social · 23/03/2025ID Grand Rounds. I discussed the following: - ONE Health - Aspergillus urine antigen - Giant magnetoresistance-enabled PCR - Rezafungin for prevention in bone marrow transplant - Ibrexafungerp (FURI) - Olorofim (Study 32) - Our experience with fosmanogepix 060
Pascalis Vergidis, MD @pascalisid.bsky.social · 13/03/2025In rare cases, vaping-associated lung injury (EVALI) may lead to irreversible damage requiring lung transplantation 010
Pascalis Vergidis, MD @pascalisid.bsky.social · 12/03/2025Can filgrastim precipitate organ rejection ? 000
Pascalis Vergidis, MD @pascalisid.bsky.social · 27/02/2025We used Giant Magnetoresistance to diagnose invasive fungal infection. The assay has the potential to detect trace amounts of fungal DNA in serum academic.oup.com/ofid/article...academic.oup.comA Novel Giant Magnetoresistance–Enabled Multiplex Polymerase Chain Reaction Assay for the Diagnosis of Invasive Fungal InfectionAbstractBackground. Despite advances in clinical microbiology, the diagnosis of invasive fungal infections remains challenging. Giant magnetoresistance (GM 030
Pascalis Vergidis, MD @pascalisid.bsky.social · 26/02/2025Aspergillus pseudodeflectus belongs to the Aspergillus section Usti. Can be multidrug resistant (similar to calidoustus) - Learning something every day! 140
Pascalis Vergidis, MD @pascalisid.bsky.social · 22/02/2025Highly recommended! Fungal Update: Mycology 2025 in London. This a pic from last year… @germhuntermd.bsky.social 1131
Pascalis Vergidis, MD @pascalisid.bsky.social · 21/02/2025Recommendation to screen, even though no cases of TB transmission reported after allogeneic stem cell transplantfda.govRecommendations to Reduce the Risk of Transmission of MtbThis is the Guidance for Industry - Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) 000
Pascalis Vergidis, MD @pascalisid.bsky.social · 20/02/2025Remember that fosmanogepix can cause neurotoxicity (approx 10%) 170
Pascalis Vergidis, MD @pascalisid.bsky.social · 19/02/2025Generative AI platforms for clinical conversations create mediocre medical notes 020
Reposted by Pascalis Vergidis, MDPascalis Vergidis, MD @pascalisid.bsky.social · 16/02/2025Mayo Clinic remains committed to Diversity and Inclusionmayoclinic.orgEquity, Inclusion and Diversity at Mayo ClinicTo provide the best care experience, Equity, Inclusion and Diversity at Mayo Clinic provides a variety of services to meet the diverse needs of patients. 2193
Pascalis Vergidis, MD @pascalisid.bsky.social · 17/02/2025You are all familiar with immune checkpoint inhibitor-associated pneumonitis. Adagrasib inhibits KRAS G12C and is used to treat non-small cell lung cancer. It can also be associated with pneumonitis. Need to rule out infection first. Discontinue adagrasib and treat with corticosteroids. 020
Pascalis Vergidis, MD @pascalisid.bsky.social · 16/02/2025Mayo Clinic remains committed to Diversity and Inclusionmayoclinic.orgEquity, Inclusion and Diversity at Mayo ClinicTo provide the best care experience, Equity, Inclusion and Diversity at Mayo Clinic provides a variety of services to meet the diverse needs of patients. 2193
Reposted by Pascalis Vergidis, MDPascalis Vergidis, MD @pascalisid.bsky.social · 09/02/2025We had a great conference. Looking forward to Mayo Clinic Infectious Disease Updates 2026 in Maui! 091
Pascalis Vergidis, MD @pascalisid.bsky.social · 09/02/2025We had a great conference. Looking forward to Mayo Clinic Infectious Disease Updates 2026 in Maui! 091
Reposted by Pascalis Vergidis, MDPascalis Vergidis, MD @pascalisid.bsky.social · 08/02/2025Mayo Clinic CME Infectious Disease Updates. Successful session on Infections in Hematology. We discussed advances in the diagnosis and treatment of fungal infection, duration of treatment for febrile neutropenia, complications of CAR-T cell therapy, fusariosis and breakthrough aspergillosis. 081
Pascalis Vergidis, MD @pascalisid.bsky.social · 08/02/2025Mayo Clinic CME Infectious Disease Updates. Successful session on Infections in Hematology. We discussed advances in the diagnosis and treatment of fungal infection, duration of treatment for febrile neutropenia, complications of CAR-T cell therapy, fusariosis and breakthrough aspergillosis. 081
Reposted by Pascalis Vergidis, MDLuis Ostrosky, MD, FIDSA @drluiso.bsky.social · 23/12/2024Coming soon to a city near you… bonus points if you can name the soon to be un-eradicated vaccine-preventable diseases. #IDSky 4185
Pascalis Vergidis, MD @pascalisid.bsky.social · 08/12/2024Aspergillus ustus tracheobronchitis. Necrotic debris within the airways. One month post-transplant for ILD. Breakthrough on posaconazole prophylaxis (level 832 ng/mL). Susceptibilities are pending. How would you treat? 2366
Pascalis Vergidis, MD @pascalisid.bsky.social · 08/12/2024Aspergillus was named by Pier Antonio Micheli, an Italian priest and biologist. The molds resembled an aspergillum, a holy water sprinkler. 111117